研究单位：[1]Pfizer[2]Peking University Third Hospital Beijing,Beijing,China,100191[3]The First Affiliated Hospital of Fujian Medical University Fuzhou,Fujian,China,350005[4]NanFang Hospital of Southern Medical University Guangzhou,Guangdong,China,510515[5]Huashan Hospital Fudan University Shanghai,Shanghai,China,200040[6]Xuanwu Hospital Capital Medical University Beijing,China,100053[7]Tiantan Hospital Capital Medical University Beijing,China,100070[8]Peking union hospital of Chinese academy of medical sciences Beijing,China,100730
研究目的：
This is a single-arm, open-label, multicenter study designed to determine the effect of tafamidis meglumine on TTR stabilization as well as tafamidis meglumine safety, tolerability and efficacy in ATTR-PN patients in China.
Approximately 10-15 participants are planned to be enrolled. All enrolled participants will receive oral tafamidis meglumine 20 mg soft capsules once daily for 72 weeks (18 months).
